Osman Aksoy, Jan Pencik, Markus Hartenbach, Ali A Moazzami, Michaela Schlederer, Theresa Balber, Adam Varady, Cecile Philippe, Pascal A Baltzer, Bismoy Mazumder, Jonathan B Whitchurch, Christopher J Roberts, Andrea Haitel, Merima Herac, Martin Susani, Markus Mitterhauser, Rodrig Marculescu, Judith Stangl-Kremser, Melanie R Hassler, Gero Kramer, Shahrokh F Shariat, Suzanne D Turner, Boris Tichy, Jan Oppelt, Sarka Pospisilova, Sabrina Hartenbach, Simone Tangermann, Gerda Egger, Heidi A Neubauer, Richard Moriggl, Zoran Culig, Georg Greiner, Gregor Hoermann, Marcus Hacker, David M Heery, Olaf Merkel, Lukas Kenner
Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine (T4) and its active form 3,5,3'-triiodo-L-thyronine (T3) are involved in the progression of PCa. Epidemiologic evidences show a higher incidence of PCa in men with elevated thyroid hormone levels. The thyroid hormone binding protein μ-Crystallin (CRYM) mediates intracellular thyroid hormone action by sequestering T3 and blocks its binding to cognate receptors (TRα/TRβ) in target tissues...
February 1, 2021: International Journal of Cancer. Journal International du Cancer